Needham Reiterates Buy on Trevi Therapeutics, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Trevi Therapeutics (NASDAQ:TRVI) and maintained an $8 price target.

April 09, 2024 | 10:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger reiterates a Buy rating on Trevi Therapeutics with an $8 price target.
The reiteration of a Buy rating and maintenance of an $8 price target by a reputable analyst like Serge Belanger from Needham is likely to instill confidence among investors and could lead to a positive short-term impact on TRVI's stock price. Analyst ratings, especially from well-regarded financial institutions, can significantly influence investor sentiment and stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100